COVID-19 is no longer a public health emergency of international concern, but long COVID’s effects are yet to be fully understood. Hence, globally, SARS-CoV-2 is still a profound threat to public health and of perilous nature as a zoonotic disease. Timely vaccination provided to individuals worldwide during the pandemic phase was under a certain degree of control; however, few studies have reported the effectiveness of vaccines administered in Mexico, and its surveillance is paramount. Furthermore, an unknown proportion of Mexican individuals have not yet received any vaccine, and the circulation of the Omicron, Pirola, and FLiRT variants is ongoing. A cross-sectional serology survey study design was employed, involving 150 individuals from Southern Mexico (Oaxaca) whose humoral immune responses after vaccination were tested by an ELISA; the receptor-binding domain of the SARS-CoV-2 spike protein served as a recombinant antigen in the ELISA. One hundred thirty-nine out of 150 individuals (92.6%; 95%-CI = 87–95%) examined were positive for the ELISA, but in 11 individuals, the vaccines did not induce any immune response. Interestingly, the immune responses (antibody prevalence and levels) of females (58%) were higher (T= −2.21; p-value = 0.02) than those of males (41%). However, in this sample population of Southern Mexico, age, vaccine type, comorbidity, and body mass index did not have any effect (p > 0.05) after COVID-19 vaccination. Taking all results together, here, we present factors that affected immune responses of individuals during the first vaccination campaign in Oaxaca, Mexico; however, vaccine surveillance during the post-pandemic phase needs further investigation.
Background: Dengue virus serotype 1 (DENV-1) is prevalent across the Americas, yet its genomic diversity in Mexico is poorly characterized. Methods: We analyzed 119 public Mexican DENV-1 genomes (polyprotein CDS, 10,179 nt) alongside 111 from 19 other American countries and territories. The Mexican panel was temporally and geographically uneven (91% from 2006 to 2009), representing available sequences, not nationwide diversity. We assessed diversity, phylogeny, dating, selection, recombination, and compatibility with three primer sets. Results: The Mexican genotype V sequences formed 115 haplotypes (Hd = 0.9994; π = 0.00831), resolving into clades A (n = 6) and B (n = 112) plus one independent introduction in Jalisco. These sequences were not monophyletic: both clades grouped with Nicaraguan and United States viruses. Their common ancestor dated to 1977.5 and clade divergence to 1984.2. Selection appeared to be predominantly purifying (ω = 0.037); no site showed concordant evidence of diversifying selection, and no recombination was detected. In silico, 84% of Mexican sequences were compatible with all three CDC real-time oligonucleotides; none matched every oligonucleotide in either conventional set. Conclusions: This historical panel shows substantial haplotype diversity and multiple introductions. The compatibility results are computational and were not validated experimentally. We recommend periodic in silico primer revalidation.